" class="no-js "lang="en-US"> Peptilogics to Present Data of Study at ECCMID 2023
Thursday, May 09, 2024

Peptilogics to Present Data in Patients Undergoing DAIR for the Treatment of Periprosthetic Joint Infection at ECCMID 2023

Peptilogics, a clinical-stage biotechnology company, has completed the enrollment of a Phase 1b trial for PLG0206 in patients undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for treatment of a Periprosthetic Joint Infection (PJI) occurring after Total Knee Arthroplasty (TKA), and will present the data from the trial at ECCMID 2023. The trial is an open-label dose-escalating study with two dose cohorts of seven patients each compared to historical controls.

Peptilogics will present the interim top-line data on PLG0206 from their ongoing Phase 1b trial at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). The presentation will cover clinical safety and tolerability data, alongside reinfection rates for the low dose (3 mg/mL) cohort at the 3-month follow-up highlighting the potent antimicrobial properties of Peptilogics’ engineered peptide PLG0206 for the treatment of periprosthetic joint infection (PJI), a life-threatening complication that patients may develop following joint replacement surgery. In-depth analysis from the low dose cohort along with the readout from the high-dose cohort will be presented at an upcoming conference.

“PJI is the last remaining problem in what is otherwise becoming a standard surgery all over the world. More than seven million total joint replacements will be performed annually in the seven major markets by 2030, which will require over 300,000 surgeries per year to try and resolve the infections,” said Jonathan Steckbeck, Chief Executive Officer of Peptilogics. “PJI is an enormous clinical and economic burden on the healthcare system due to the poor outcomes associated with the current standard of care, which includes multiple major surgeries and hospitalizations followed by high doses of antibiotics. We are working to develop a broad-spectrum curative solution that can address all the challenges of bacterial biofilm in infected joints.”

“Patients with PJI are a population with significant unmet medical need, as the current standard of care falls short of addressing these infections,” said David Huang, Chief Medical Officer at Peptilogics. “With enrollment complete for our Phase 1b study, we look forward to continuing the clinical development of PLG0206 for this important patient population.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more